# GLOW Peptide Dosage & Protocol Guide | PeptideFox ## GLOW Peptide Dosage A standard 70 mg GLOW vial contains three peptides in fixed mass ratios: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg full-length TB-4. | Compound | Mass in 70 mg vial | Standard dose | | --- | :---: | :---: | | GHK-Cu¹ | 50 mg | 2 mg | | BPC-157² | 10 mg | 400 mcg | | TB-4³ ⁴ | 10 mg | 400 mcg | The standard 2.8 mg GLOW dose contains 2 mg GHK-Cu and 400 mcg each of BPC-157 and TB-4. The 12-week schedule keeps that dose constant while frequency falls: daily in weeks 1–4, 5x per week in weeks 5–8, and 2-3x per week in weeks 9–12. Skin repair slows with age across several connected systems: collagen genes fire less, capillary supply thins, and repair cells lose coordination. By design, GLOW assigns one peptide to address each bottleneck. The GLOW peptide blend contains three peptides in a fixed 50/10/10 mg ratio: - **GHK-Cu** — Builds new collagen and clears damaged tissue at the same time.¹ Most collagen interventions only do the first; this is what makes GLOW a skincare stack. - **BPC-157** — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site. - **TB-4** (full-length thymosin β4, 43 aa) — Moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.³ ⁴ GLOW uses the full-length TB-4 parent, not the shorter TB-500 fragment; the two are blurred on labels routinely.⁵ Confirm what sequence is in the vial by reviewing third-party lab reports. GLOW coordinates three jobs that skin remodeling needs at the same time. GHK-Cu changes the repair instructions, BPC-157 supports the capillary supply, and TB-4 gives repair cells the internal structure they need to move through tissue. The blend has not been tested as a complete formulation; its rationale comes from the complementary mechanisms of the three peptides. ### GHK-Cu: collagen and structure #### What it is GHK-Cu is a three-amino-acid peptide bound to copper. It carries copper into the repair processes that build and organize the skin's structural matrix. #### How it works GHK-Cu changes which repair instructions skin cells follow, increasing collagen, elastin, and antioxidant production while helping clear damaged tissue. Its copper also supports lysyl oxidase, the enzyme that cross-links new collagen fibers and gives the matrix strength (gene regulation, tissue clearing, and collagen cross-linking¹). #### Role in GLOW GHK-Cu addresses both sides of skin remodeling: removing damaged matrix and building its replacement. It is the main rebuilding signal in GLOW, while BPC-157 supports the blood supply and TB-4 helps position repair cells. #### Evidence GHK-Cu is associated with regulation across more than 4,000 genes, including collagen synthesis, antioxidant defense, wound healing, inflammation, and tissue breakdown. Circulating levels decline with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by 60.¹ Small split-face human dermatology studies, usually with fewer than 50 participants per arm, report changes in wrinkle depth and skin density. The strongest human evidence is topical; it does not establish how much injected GLOW changes human skin. No multi-center RCT has evaluated GLOW or injectable GHK-Cu for this use.¹ ### BPC-157: blood supply #### What it is BPC-157 is a synthetic 15-amino-acid peptide modeled from a protective protein fragment found in gastric juice. Its role in GLOW is to support the blood supply behind tissue repair rather than build collagen directly. #### How it works BPC-157 signals blood-vessel cells to relax existing vessels, move into damaged tissue, and form new capillaries. In tendon repair cells, it also increased the number of places where growth hormone can attach; it made the cells more responsive when growth hormone was present without activating the signal on its own (new blood vessel formation²). #### Role in GLOW Active skin remodeling needs oxygen, nutrients, and a route for repair cells to reach the area. BPC-157 supports that supply layer so oxygen and nutrients can reach the tissue while GHK-Cu and TB-4 do their repair work. #### Evidence More than 100 preclinical repair studies support BPC-157's blood-vessel signaling and repair-cell effects. The limited human evidence includes: - A randomised double-blind placebo-controlled Phase 2 enema trial in ulcerative colitis with 53 participants, published only as a meeting abstract. Its confidence interval spans zero and is wider than the point estimate, so it was too small to detect the difference it observed — uninformative rather than null. - An intra-articular knee series with 16 patients analysed. Fourteen improved, and 7 of 12 reported durable improvement beyond six months by telephone follow-up. - A hamstring registration with estimated enrollment and no disclosed dose. It remains provenance-flagged and registered-unverified. No human study shows that SubQ BPC-157 builds new capillaries in skin or improves a GLOW outcome. No published receptor binding constant or characterised minimum effective concentration anchors the dose, so dose decisions rest on preclinical envelopes.² ### TB-4: cell migration #### What it is TB-4 is a naturally occurring 43-amino-acid peptide involved in cell movement and tissue repair. It is not the same molecule as TB-500, the shorter 17–23 fragment, even when product labels use the names interchangeably.⁵ #### How it works Repair cells move by building and releasing an internal scaffold made from actin. TB-4 holds loose actin in reserve so the scaffold can be assembled where it is needed. TB-4 can also release Ac-SDKP, a smaller peptide studied for anti-scarring and anti-inflammatory effects (actin sequestration and Ac-SDKP release³ ⁴). #### Role in GLOW TB-4 supports the movement of repair cells through damaged tissue and the organization of the rebuilding process. Its role complements GHK-Cu: TB-4 helps position the repair cells, while GHK-Cu handles more of the matrix-building work. #### Evidence Full-length TB-4 has human clinical research across corneal, cardiac, and wound-repair programs, including clean Phase 1 safety data, plus dermal wound-healing models. Those studies support the broader repair mechanism. They do not establish the efficacy of a 400 mcg SubQ dose in GLOW, and their findings cannot be assigned to a TB-500 fragment vial.³ ⁴ ⁵ ⁶ ## Regulatory Status GLOW as a pre-mixed blend has not been evaluated by the FDA. The current compounding review applies to its individual compounds rather than GLOW as a finished formulation. ### GHK-Cu - Injectable GHK-Cu was moved to Category 2 in September 2023. - GHK-Cu will return to PCAC for a vote before the end of February 2027. - HHS has announced that GHK-Cu is expected to return to Category 1, which would restore compounding access for injectable formulations.⁸ ### BPC-157 - On 23 July 2026, PCAC voted to recommend adding BPC-157 to the 503A Bulks List, against FDA staff, who had recommended against listing. - BPC-157 was removed from Category 2 on 22 April 2026 by nominator withdrawal rather than because a safety concern was resolved. - The BPC-157 evaluation covered ulcerative colitis only, and the vote counts are contested across the source documents, so no tally is quoted here as primary-sourced. - Final FDA action on BPC-157 is still pending. ### TB-4 - The July 23, 2026 PCAC recommendation covered TB-500, not the full-length TB-4 used in GLOW. - TB-500 is a fragment of the full-length thymosin beta-4 (43 amino acids), and the full-length TB-4 has substantially more human safety data than the fragment. - Vendors often use the TB-4 and TB-500 names interchangeably, or confuse the two. The operative status for BPC-157 and TB-500 is recommended for listing, pending FDA action. A committee recommendation is not a rule; notice-and-comment rulemaking follows and can take over a year. These are access-pathway questions rather than therapeutic approval. The dosing below draws from the per-component research and is reflected in the FDA review committee documents for each peptide, which aligns with PeptideFox's previous research. --- --- ## GLOW Dosing Protocol The standard protocol for GLOW is 2.8 mg per injection: 2 mg GHK-Cu with 400 mcg each of BPC-157 and TB-4. - Reconstitute a GLOW-70 vial by adding 2.5 mL of BAC water - That delivers a concentration of 28 mg/mL - The resulting dose per injection: 2.8 mg ÷ 28 mg/mL = 0.1 mL or 10-units on a U-100 insulin syringe | Anchor | BAC water | Draw | GHK-Cu | BPC-157 | TB-4 | | --- | :---: | :---: | :---: | :---: | :---: | | GHK-Cu | 2.5 mL | 10 units | **2 mg** | 0.4 mg | 0.4 mg | Each 70 mg vial of GLOW supplies 25 daily doses and remains within the 28-day refrigerated-use window. The time of day is inconsequential — consistency is far more important. Note: GLOW has no trial-established dose that combines the three compounds; the dose is derived by combining the ranges of each individual peptide. ### 12-week GLOW protocol for skincare The GLOW protocol runs for 12 weeks, split up into three phases, followed by 4–8 weeks off. The 2.8 mg dose remains fixed while frequency decreases from daily -> 5x per week -> 2-3x per week. | Phase | Weeks | Frequency | |---|---|---| | Activation | 1–4 | Daily | | Remodeling | 5–8 | 5x per week | | Maintenance | 9–12 | 2-3x per week | No controlled trial has tested this schedule or established when skin changes should appear — and while reports on public forums are extensive, each individual may respond differently. In addition, the [Supporting Factors](#supporting-factors) — such as sleep and hydration — will materially affect results. #### Phase 1: Activation (Weeks 1–4) **Dose:** Daily - GHK-Cu activates collagen production while its copper component enables proper structural cross-linking¹ - BPC-157 builds the network of small blood vessels needed to feed active tissue² - TB-4 mobilizes and organizes repair cells³ **Expected:** Skin hydration improves, tone evens, and texture softens. **Baseline photos.** Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6. #### Phase 2: Remodeling (Weeks 5–8) **Dose:** 5x per week Same per-injection amounts. All compounds at peak coordinated activity. - GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within¹ - BPC-157 maintains blood flow to active tissue² - TB-4 coordinates efficient cell organization³ **Expected:** Fine lines soften, elasticity improves, visible glow returns, and skin thickness increases. **Progress photos.** Measure week 6 against the week-0 baseline. #### Phase 3: Maintenance (Weeks 9–12) **Dose:** 2-3x per week Pulsed administration keeps the repair signal present without turning the protocol into constant stimulation. - **Signal sensitivity** — pulsed dosing is the conservative way to avoid blunting the response over time. - **Integration time** — newly synthesized collagen needs 48–72 hours between pulses to organize and cross-link. - **Maintenance fit** — long-running protocols usually work better as a cadence than as daily pressure forever. Take a 4–8-week break between GLOW cycles; none of the compounds have been studied for continuous use. **Progress photos.** Compare week 12 with the week-0 baseline and week 6. The full schedule uses 56–60 injections, and each 70 mg GLOW vial contains 25 standard doses by mass. CDC summarizes USP guidance: date an opened multi-dose vial at first puncture and discard it within 28 days unless the manufacturer states another opened-vial date.⁷ The dose count and 28-day window together require three vials for the 12-week protocol. Cycled topical actives such as retinoids, vitamin C, and niacinamide are sometimes paired with GLOW during the active weeks. GLOW targets dermal structure; the topicals target surface turnover and pigmentation. Phasing and lifestyle inputs are covered in [Supporting Factors](#supporting-factors) below. #### GLOW is skincare-only — for injury, use the injury protocols GLOW has no injury protocol. The fixed 50/10/10 skincare ratio does not deliver what soft tissue needs: TB-4 lands far below its cell-migration threshold, and there is no KPV to gate inflammation. BPC-157 is the one component that does land in range, at 400 mcg against a derived position of 250-500 mcg daily — but GLOW's frequency falls to 5x and then 2-3x weekly, where injured tissue is dosed once daily. Pushing the dose to fix any of that overdoses GHK-Cu. Soft-tissue injury protocols dose the compounds individually instead. The [BPC-157 + TB-500 Wolverine Stack](/content/wolverine-stack) covers simple repair; the [Injury Recovery Protocol](/content/injury-recovery-peptide-protocol) is the five-compound version with the TB-500 bolus (1–2.5 mg, 2-3x per week) and NAD+ that the cocktail can't carry. For reactive or inflamed skin rather than injury, [KLOW](/tools/klow-dosage-calculator) adds KPV. --- ## Conditional Add-Ons NAD+ is the primary metabolic add-on considered for GLOW. It may be relevant when remodeling occurs under metabolic strain — GLP-1 use, caloric deficit, or chronic fatigue. Age alone is a weaker reason than it is usually presented as: whole-blood NAD+ does not reliably fall with age, and the decline that does show up is tissue-specific and load-dependent. Strain is the signal here, not birthday. The dose is **100–200 mg IM, 2-3x per week**. NAD+ requires a different syringe and site because its acidity can degrade peptides on contact. GLOW alone handles standard skin quality. The remaining layers are conditional — added only when a specific bottleneck shows up, not by default: **Topical GHK-Cu / AHK-Cu + minoxidil**. Fits hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. The underlying deficit matters too — hair follicles need direct scalp exposure plus enough protein and calories to grow. **MT-I (afamelanotide), not MT-II**. Fits when pigment with photoprotection sits alongside skin-quality goals. MT-II's central nervous-system side effects make it the wrong default. **Sermorelin / Tesamorelin / Ipamorelin**. Only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer. KLOW is the better fit when inflammation emerges or baseline reactivity is the limit. Continuous standalone KPV alongside GLOW produces the same four-peptide composition with more handling. [Tell FoxAI your situation and it builds the right stack →](/chat?seed=glow-bridge) --- ## Phenotype Considerations **Perimenopausal users.** Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. The full 12-week, three-phase cycle remains the baseline rather than compressing the protocol into eight weeks; activation remains weeks 1–4. **Recent surgery.** The convention defers at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation. **GLP-1 users / aggressive cutting.** Rapid weight loss outpaces the skin's ability to remodel, and substrate availability tightens. NAD+ from the start fits here, with the topical hair overlay where shedding emerges. --- ## Supporting Factors These inputs support tissue synthesis, collagen cross-linking, matrix hydration, copper balance, and overnight repair: | Component | Target | | --- | --- | | Protein | At least 1.6 g/kg daily | | Vitamin C | 500–1,000 mg daily | | Hydration | 2–3 L of water daily | | Zinc | 15–25 mg if supplementing copper | | Sleep | 7–9 hours | Optional adjuncts: red-light therapy (630–670 nm) for 10–20 minutes daily, and microneedling every three to four weeks during Phase 2. --- ## Safety & Considerations **Active cancer or cancer history.** GLOW is excluded during active cancer treatment. The blood-vessel signaling associated with GHK-Cu, BPC-157, and TB-4 creates a theoretical concern, not a measured human tumor risk. Five years after treatment or remission is used as a conservative review window rather than a proven biological cutoff. Any use within that window requires explicit clearance and ongoing supervision from the clinician managing the cancer history; after five years, medical review still applies when recurrence risk or active surveillance remains relevant. **Wilson's disease or copper overload.** GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders. **Pregnancy or breastfeeding.** No safety data for any of the three peptides during pregnancy. **WADA-tested athletes.** TB-4 is on the prohibited list; GLOW is not usable in-competition. **Reactive or rosacea-prone skin.** GLOW does not address inflammatory tone; KLOW is the better tool for these cases. Conventional alternatives include topical retinoids and in-office collagen-induction procedures. They act through different tissue layers and carry different downtime and cost profiles. --- ## FAQ **Basics** ### What is the GLOW peptide? GLOW is a single-vial skincare blend containing GHK-Cu, BPC-157, and TB-4 in a fixed 50/10/10 mg ratio. | Compound | Mass | Role | |---|:---:|---| | GHK-Cu | 50 mg | Collagen rebuilding and matrix repair | | BPC-157 | 10 mg | Capillary supply for the repair area | | TB-4 | 10 mg | Repair-cell migration and anti-scarring | Total: 70 mg. TB-4 should be full-length thymosin β4 (43 amino acids), although some products label it "TB-500"; verify the sequence on the certificate of analysis (CoA) from a third-party lab. ### What is in the GLOW peptide blend / stack? Both terms refer to the same GLOW pre-mixed single-vial composition of GHK-Cu, BPC-157, and TB-4. "GLOW-70" and "GLOW 70 mg" identify the same 70 mg blend in a 50/10/10 ratio of GHK-Cu/BPC-157/TB-4. ### What are the benefits of the GLOW peptide blend? GLOW's value is structural skin work — collagen rebuilding, microvascular support, and organized cell migration in a single vial: - **Collagen rebuilding and matrix quality**. GHK-Cu turns on collagen production at the gene level and clears damaged tissue in parallel. - **Capillary supply to the repair area**. BPC-157 sprouts new small blood vessels so the rebuilding has nutrient delivery. - **Repair-cell migration and anti-scarring**. TB-4 (full-length, 43 aa) moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring. GLOW is not designed for reactive or rosacea-pattern skin, acute injury, or weight loss. [KLOW](/tools/klow-dosage-calculator) adds KPV for inflammatory skin patterns; injury protocols require a different TB-4 dose. ### How long does it take to see results from GLOW? No controlled GLOW trial establishes a results timeline. Texture, fine lines, and firmness change gradually, so baseline photographs provide a more reliable comparison than daily observation. ### Can GLOW be made from separate peptide vials? Yes. The three compounds can be sourced and reconstituted separately, which allows independent dosing but adds cold-chain items and sterile draws. A premixed vial fixes the ratio and reduces handling. ### At what age is GLOW typically started? Use is most often described after age-related collagen decline becomes visible, commonly from the mid-30s onward. Sun damage or scarring may matter more than age alone. No controlled evidence defines an age threshold for the blend. **Dosing** ### What is the standard GLOW dose? The standard protocol uses **2.8 mg per injection: 2 mg GHK-Cu + 400 mcg of BPC-157 + 400 mcg of TB-4**. For a GLOW-70 vial reconstituted with 2.5 mL of BAC water (28 mg/mL), a 2.8 mg dose is equivalent to 10 syringe units (0.1 mL). As GLOW has no trial-established dose, the derived range is 1.4-4.2 mg per injection: - Low Dose: 1.4 mg (1 mg GHK-Cu + 200 mcg BPC-157 + 200 mcg TB-4) - Standard Dose: 2.8 mg (2 mg GHK-Cu + 400 mcg BPC-157 + 400 mcg TB-4) - Elevated Dose: 4.2 mg (3 mg GHK-Cu + 600 mcg BPC-157 + 600 mcg TB-4) ### What is the GLOW dose per day? Typically 2.8 mg per day (2 mg GHK-Cu plus 0.4 mg each of BPC-157 and TB-4); note that daily dosing is **only for the activation phase of the GLOW protocol (weeks 1-4)**, decreasing to 5x per week for the remodeling phase (weeks 5-8), and further reduced to 2-3x per week during maintenance (weeks 9-12). The frequency changes across the three phases; the dose per injection remains 2.8 mg. ### What is the standard GLOW dosage and frequency? The standard schedule keeps each injection at 2.8 mg: daily in weeks 1–4, 5x per week in weeks 5–8, and 2-3x per week in weeks 9–12. With 2.5 mL of BAC water in a 70 mg vial, each injection is a 0.1 mL, or 10-unit, draw. Missed doses are skipped instead of doubling the next injection. ### How long is a standard GLOW cycle? A standard GLOW cycle lasts 12 weeks, followed by 4–8 weeks off. The three phases are activation in weeks 1–4, remodeling in weeks 5–8, and maintenance in weeks 9–12. Each injection remains 2.8 mg while frequency falls. ### Where should GLOW be injected? GLOW is injected subcutaneously in a rotated site. The abdomen, thigh, and lateral hip all work; rotation reduces repeated local irritation. See [where to inject GLOW peptide](/content/where-to-inject-peptides#glow-and-klow) for the full anatomical breakdown. **Side Effects & Safety** ### What are the side effects of GLOW? The most common reported effect is a 30–60-second sting from the copper-peptide complex. Less common reports include fatigue 12–24 hours after dosing, injection-site redness, and brief flushing. The blue vial color is expected. More BAC water lowers concentration; slow injection and site rotation may reduce local irritation. GLOW is excluded during active cancer treatment; cancer treatment or remission within the past five years requires explicit clearance and ongoing supervision from the clinician managing that history. Other contraindications and caution flags include Wilson's disease or another copper-handling disorder, pregnancy, recent surgery, and WADA-tested competition. [KLOW](/tools/klow-dosage-calculator) is the more relevant blend for reactive or rosacea-prone skin. ### What happens if a GLOW dose is missed? A missed dose is skipped instead of doubled. The next injection stays on the scheduled dose and cadence. **Reconstitution & Storage** ### How is a 70 mg GLOW vial reconstituted? Add bacteriostatic water to the lyophilized 70 mg vial. Standard volumes are: - **2.5 mL** standard (2 mg GHK-Cu per 0.1 mL draw) - **5 mL** for a 0.2 mL (20-unit) draw — easier syringe-mark reading and reduced concentration-dependent sting Let the water run down the inside vial wall, then swirl gently without shaking. The dissolved solution should be clear blue from the copper-bound GHK-Cu. See the [Reconstitution Guide](/content/reconstitution) for handling details. ### How much BAC water should be used for a 70 mg GLOW vial? For the standard skincare anchor, add **2.5 mL** of BAC water. A 0.1 mL (10-unit) draw then delivers 2 mg GHK-Cu plus 0.4 mg each of BPC-157 and TB-4, for 25 doses per vial. Higher water volumes reduce concentration but require a larger draw. GLOW is not an injury protocol. Its fixed ratio cannot deliver an injury-level TB-4 bolus without excessive GHK-Cu; the [Wolverine Stack](/content/wolverine-stack) and [Injury Recovery Protocol](/content/injury-recovery-peptide-protocol) are designed for soft-tissue injury. ### How is BAC water volume calculated for a different GLOW draw? For any target anchor dose `D` (mg) and anchor mass `M` in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg): $$V_{\text{water}} = \frac{V_{\text{draw}} \times M}{D}$$ **Worked example — 3 mg GHK-Cu, 20-unit (0.2 mL) draw:** $$V_{\text{water}} = \frac{0.2 \text{ mL} \times 50 \text{ mg}}{3 \text{ mg}} = 3.33 \text{ mL BAC water}$$ The [GLOW Calculator](#dosage-calculator) above solves this for any anchor and draw volume. ### How much BAC water should be used for a 3 mg GHK-Cu dose? At this anchor dose, the per-injection payload is: - 3 mg GHK-Cu - 0.6 mg BPC-157 - 0.6 mg TB-4 **20-unit draw:** 3.33 mL BAC water produces 15 mg GHK-Cu/mL; 0.2 mL delivers the 3 mg target. The vial supplies about 16 doses. **10-unit draw:** 1.67 mL BAC water produces 30 mg GHK-Cu/mL; 0.1 mL delivers the same dose at a higher concentration. **30-unit draw:** 5 mL BAC water produces 10 mg GHK-Cu/mL; 0.3 mL delivers the same dose at a lower concentration. ### How much BAC water should be used for a 0.35 mg BPC-157 dose? At this anchor dose, the per-injection payload is: - 1.75 mg GHK-Cu - 0.35 mg BPC-157 - 0.35 mg TB-4 **10-unit draw:** 2.85 mL BAC water produces 3.5 mg BPC-157/mL; 0.1 mL delivers the 0.35 mg target. The vial supplies 28 doses. **5-unit draw:** 1.43 mL BAC water produces 7 mg BPC-157/mL; 0.05 mL delivers the same dose at a higher concentration. **15-unit draw:** 4.28 mL BAC water produces about 2.3 mg BPC-157/mL; 0.15 mL delivers the same dose at a lower concentration. ### How should reconstituted GLOW be stored? Refrigerate at 2–8°C (36–46°F). Keep away from direct light. Do not freeze. Use within 28 days of reconstitution. Discard if the solution becomes cloudy, loses its blue tint, or develops particulate. **GLOW vs KLOW** ### GLOW vs. KLOW: what's the difference? GLOW fits when skin is calm and the goal is firmness, fine lines, or texture. KLOW fits when inflammation is in the picture — rosacea, post-procedure redness, reactive skin. The two share the same three peptides at identical doses, so switching mid-cycle is a vial swap. Full breakdown in [GLOW vs. KLOW](/content/glow-vs-klow). ### Can KPV be added to GLOW separately? Separate KPV is sometimes used for short inflammatory events such as an acne flare or post-procedure irritation, then stopped when the event resolves. When inflammation is the baseline rather than a short event, [KLOW](/tools/klow-dosage-calculator) is the cleaner fit. Running standalone KPV alongside GLOW continuously produces the same four-peptide composition with more handling. ### Can GLOW be used for injuries? GLOW is a skincare stack and does not supply an injury-level TB-4 dose. A standard 2.8 mg GLOW dose contains 400 mcg of full-length TB-4. The [BPC-157 + TB-500 Wolverine Stack](/content/wolverine-stack) doses the TB-500 fragment at 1–2.5 mg per injection, 2-3x per week, to a 4–6 mg weekly target. The 2–4 mg figure that circulates alongside it belongs to full-length TB-4, not to the fragment, and the two are different molecules at different masses. At GLOW's fixed ratio, delivering 2 mg of TB-4 would require 14 mg total GLOW: 10 mg GHK-Cu and 2 mg each of BPC-157 and TB-4. That puts GHK-Cu far above this skincare protocol's range. Separate vials let the TB-4 or TB-500 dose rise without multiplying the other two peptides. **Stacking** ### Can GLOW be stacked with NAD+? NAD+ is paired with GLOW when remodeling occurs under metabolic strain, including fatigue or caloric deficit. No controlled trial has evaluated the combination. NAD+ requires a different syringe and site because its acidic solution can destabilize peptides on contact. ### Can GLOW be stacked with GLP-1s? GLOW and GLP-1 medications act through different receptor systems. The reason for pairing them is to support skin remodeling during rapid weight loss, but no controlled trial has tested the combination or shown that effect. ## Related Topics - [KLOW Dosing Calculator](/tools/klow-dosage-calculator) — The 4-peptide variant with KPV for reactive or post-procedure skin - [Injury Recovery Peptide Protocol](/content/injury-recovery-peptide-protocol) — Five-compound structural repair framework including NAD+ metabolic support - [BPC-157 + TB-500 Wolverine Stack](/content/wolverine-stack) — Simpler injury recovery stack centered on the two core repair peptides - [BPC-157 Guide](/content/bpc-157) — Standalone dosing, pharmacokinetics, oral vs injectable - [TB-500 / TB-4 Guide](/content/tb-500) — Fragment vs full-length, CoA verification, threshold-saturation mechanism - [GHK-Cu Guide](/content/ghk-cu-skin) — Copper peptide mechanism for skin and matrix quality - [NAD+ Guide](/content/nad-guide) — Cellular energy support for intensive repair cycles - [Peptide Reconstitution Guide](/content/reconstitution) — General bacteriostatic water and syringe handling - [Where to Inject GLOW Peptide](/content/where-to-inject-peptides#glow-and-klow) — Near-injury vs systemic injection routing --- ## References ¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: [PubMed 29986520](https://pubmed.ncbi.nlm.nih.gov/29986520/); age-related plasma decline (roughly 200 ng/mL at age 20 to about 80 ng/mL by 60): Pickart L, Margolina A. _Int J Mol Sci_ 2018. [DOI: 10.3390/ijms19071987](https://doi.org/10.3390/ijms19071987) ² BPC-157 angiogenic signaling — VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: [PMC8275860](https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/) ³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: [PubMed 12581423](https://pubmed.ncbi.nlm.nih.gov/12581423/) ⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: [PMC4889319](https://pmc.ncbi.nlm.nih.gov/articles/PMC4889319/); fragment-specific activity review: [PMC8724243](https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/) ⁵ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed peptide products: Esposito M et al. _Drug Test Anal_ 2012. [PubMed 22962027](https://pubmed.ncbi.nlm.nih.gov/22962027/) ⁶ TB-4 Phase 1 human safety — first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin β4 in healthy volunteers, no serious adverse events: [PubMed 34346165](https://pubmed.ncbi.nlm.nih.gov/34346165/); intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223–229): [NCT00743769](https://clinicaltrials.gov/study/NCT00743769) ⁷ Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices: multi-dose vial handling and beyond-use guidance. [CDC injection-safety guidance](https://www.cdc.gov/injection-safety/hcp/clinical-safety/index.html) ⁸ On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1.